Patent search ap:("ARRAY BIOPHARMA INC.") AND inv:"James F. Blake" Page 9

81.

发明授权
Pyrrolopyridines as kinase inhibitors 有权
Title translation: 吡咯并吡啶类作为激酶抑制剂

公开(公告)号：US08758830B2

公开(公告)日：2014-06-24

申请号：US13974895

申请日：2013-08-23

Applicant: Array BioPharma Inc.

Inventor： Yvan Le Huerou , James F. Blake , Indrani W. Gunawardana , Peter J. Mohr , Eli M. Wallace , Bin Wang , Mark Joseph Chicarelli , Michael Lyon

IPC: A61K31/4545 , A61K31/437 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/444 , A61K31/501 , A61K35/00 , A61K33/24

CPC classification number: C07D471/04 , C07D401/06 , C07D519/00

Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract translation: 式I的化合物可用于抑制CHK1和/或CHK2。公开了使用式I化合物及其立体异构体及其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

82.

发明申请
PYRROLOPYRIDINES AS KINASE INHIBITORS 有权

公开(公告)号：US20140100369A1

公开(公告)日：2014-04-10

申请号：US13974895

申请日：2013-08-23

Applicant: Array BioPharma Inc.

Inventor： Yvan Le Huerou , James F. Blake , Indrani W. Gunawardana , Peter J. Mohr , Eli M. Wallace , Bin Wang , Mark Joseph Chicarelli , Michael Lyon

IPC: C07D471/04

CPC classification number: C07D471/04 , C07D401/06 , C07D519/00

Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

83.

发明申请
SERINE/THREONINE KINASE INHIBITORS 有权
Title translation: 丝氨酸/螺旋激酶抑制剂

公开(公告)号：US20130252934A1

公开(公告)日：2013-09-26

申请号：US13782513

申请日：2013-03-01

Applicant: ARRAY BIOPHARMA INC. , GENENTECH, INC.

Inventor： James F. Blake , Mark Joseph Chicarelli , Rustam Ferdinand Garrey , John Gaudino , Jonas Grina , David A. Moreno , Peter J. Mohr , Li Ren , Jacob Schwarz , Huifen Chen , Kirk Robarge , Aihe Zhou

IPC: A61K31/506 , C07D401/04 , A61K45/06 , C07D413/14 , C07D409/14 , C07D417/14 , C07D405/14 , C07D401/14

CPC classification number: C07D401/04 , A61K31/444 , A61K31/506 , A61K31/513 , A61K31/53 , A61K45/06 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07F9/65586

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract translation: 提供式I化合物或其立体异构体，互变异构体，前药或其药学上可接受的盐，其可用于治疗过度增生，疼痛和炎性疾病。公开了使用式I化合物或其立体异构体，互变异构体，前药或其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

84.

发明授权
Fused heterocyclic compounds as RET kinase inhibitors 有权

公开(公告)号：US11964988B2

公开(公告)日：2024-04-23

申请号：US17274990

申请日：2019-09-06

Applicant: ARRAY BIOPHARMA INC.

Inventor： James F. Blake , Donghua Dai , Julia Haas , Yutong Jiang , Dean Kahn , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L McKenney , Andrew T. Metcalf , David A. Moreno , Brett Prigaro , Ginelle A. Ramann , Li Ren , Shane M. Walls , Hailong Zhang

IPC: C07D498/22 , A61K31/519 , A61K31/55 , A61K31/554 , A61K45/06 , A61P35/00 , C07D487/14 , C07D498/14 , C07D513/22

CPC classification number: C07D498/22 , A61K31/519 , A61K31/55 , A61K31/554 , A61K45/06 , A61P35/00 , C07D487/14 , C07D498/14 , C07D513/22

Abstract: Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

85.

发明授权
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors 有权

公开(公告)号：US11648243B2

公开(公告)日：2023-05-16

申请号：US17108528

申请日：2020-12-01

Applicant: Array Biopharma Inc.

Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. Mcfaddin , Megan L. Mckenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls

IPC: A61K31/4545 , A61K31/4162 , C07D471/04 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12

CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04

Abstract: Provided herein are compounds of the Formula I:

or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

86.

发明授权
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors 有权

公开(公告)号：US11603374B2

公开(公告)日：2023-03-14

申请号：US16962345

申请日：2019-01-18

Applicant: Array BioPharma Inc.

Inventor： James F. Blake , Donghua Dai , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Andrew T. Metcalf , David A. Moreno , Brett Prigaro , Ginelle A. Ramann , Li Ren

IPC: C07D487/04

Abstract: Provided herein are compounds of the Formula I: [INSERT FORMULA I] and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and Ry have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

87.

发明授权
Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors 有权

公开(公告)号：US11524963B2

公开(公告)日：2022-12-13

申请号：US16961973

申请日：2019-01-18

Applicant: Array Biopharma Inc.

Inventor： James F. Blake , Donghua Dai , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Andrew T. Metcalf , David A. Moreno , Brett Prigaro , Li Ren

IPC: A61K31/519 , C07D487/04

Abstract: Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1 and R2 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.